Calton & Associates Inc. Invests $224,000 in Blueprint Medicines Co. (NASDAQ:BPMC)

Calton & Associates Inc. acquired a new position in Blueprint Medicines Co. (NASDAQ:BPMCFree Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 2,423 shares of the biotechnology company’s stock, valued at approximately $224,000.

Several other hedge funds also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Blueprint Medicines by 1.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 476,063 shares of the biotechnology company’s stock worth $43,912,000 after purchasing an additional 7,646 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Blueprint Medicines by 1,906.0% in the 4th quarter. Victory Capital Management Inc. now owns 131,050 shares of the biotechnology company’s stock worth $12,088,000 after purchasing an additional 124,517 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in shares of Blueprint Medicines in the fourth quarter worth about $1,430,000. Van ECK Associates Corp boosted its holdings in shares of Blueprint Medicines by 28.4% in the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after buying an additional 193 shares during the period. Finally, Intrust Bank NA acquired a new position in shares of Blueprint Medicines in the fourth quarter worth about $247,000.

Insider Activity

In other news, CFO Michael Landsittel sold 10,000 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total value of $1,050,000.00. Following the transaction, the chief financial officer now owns 47,286 shares of the company’s stock, valued at $4,965,030. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Ariel Hurley sold 1,834 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total transaction of $190,515.92. Following the transaction, the insider now owns 14,913 shares of the company’s stock, valued at $1,549,162.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the transaction, the chief financial officer now directly owns 47,286 shares in the company, valued at approximately $4,965,030. The disclosure for this sale can be found here. Insiders have sold a total of 104,123 shares of company stock valued at $9,554,679 over the last 90 days. 3.88% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on BPMC shares. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. SVB Leerink upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and raised their target price for the stock from $50.00 to $97.00 in a report on Monday, May 6th. Stifel Nicolaus raised their target price on shares of Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Citigroup raised their target price on shares of Blueprint Medicines from $65.00 to $76.00 and gave the stock a “sell” rating in a report on Friday, May 3rd. Finally, Leerink Partnrs upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a report on Monday, May 6th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $100.31.

Read Our Latest Stock Report on Blueprint Medicines

Blueprint Medicines Stock Down 1.5 %

NASDAQ BPMC traded down $1.64 during trading on Friday, reaching $106.70. The company’s stock had a trading volume of 406,715 shares, compared to its average volume of 748,139. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $6.53 billion, a PE ratio of -22.18 and a beta of 0.65. The business has a 50-day moving average price of $92.97 and a 200-day moving average price of $82.62. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $110.93.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. During the same period in the previous year, the company earned ($2.65) earnings per share. The company’s revenue was up 85.5% compared to the same quarter last year. On average, research analysts forecast that Blueprint Medicines Co. will post -5.15 earnings per share for the current fiscal year.

Blueprint Medicines Profile

(Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

See Also

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.